NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® brain function monitoring for pediatric patients (1-18 years of age). With ...
Masimo (NASDAQ: MASI) announced today that it has received CE Mark for its SEDLine brain function monitor - expanding access to and availability of SEDLine's advanced neuromonitoring technology to ...
Masimo, a global medical technology company developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and ...
(BUSINESS WIRE )--Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical ...
Next Generation SedLine Now Available for Use on Patients 1-18 Years Old in CE Mark Countries NEUCHATEL, Switzerland — Masimo (NASDAQ: MASI) announced today the CE marking of Next Generation SedLine ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback